SNTI Stock — Senti Biosciences Holdings Inc.: Cash, EV, Pipeline

Share price

$0.32

Market cap

$10.0M

Cash

$6.5M

Enterprise value

$3.5M

Balance sheet

Cash	$6.5M
Debt	$0.0M
Net cash	$6.5M
Enterprise value	$3.5M
Basic shares	31.1M shares
Fully diluted shares	42.3M shares
Fully diluted market cap	$13.5M
Cash per share	$0.21

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SNTI daily closes…

Loading price history…

Pipeline assets

SENTI-202

Phase 1 · Active Modality: cell therapy (off-the-shelf CAR-NK; logic-gated gene circuit: CD33/FLT3 OR gate + EMCN NOT gate + calibrated-release IL-15)

Target CD33 / FLT3 (protective antigen EMCN on healthy HSCs)

Indications

Relapsed/refractory hematologic malignancies, including AML (CD33 and/or FLT3 positive) (Phase 1)

Status note Phase 1 ongoing (US and Australia); IND cleared Dec 2023. Orphan Drug Designation Jun 2025; RMAT designation Dec 2025. Jul 2026 merger: affiliate of Celadon Partners acquires substantially all business/pipeline; SENTI-202 continues under Parent with up to $60M CVRs to Senti stockholders on BLA filing/approval/$200M sales milestones.

Rett Syndrome program

Preclinical · Active Modality: gene therapy (Regulator Dial technology)

Indications

Rett Syndrome (Preclinical)

Status note Early-stage program retained by the public company under the merger agreement.

TIL program

Preclinical · Active Modality: cell therapy (Regulator Dial-enabled armored tumor-infiltrating lymphocytes)

Indications

Solid tumors (Preclinical)

Status note Early-stage program retained by the public company under the merger agreement.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SENTI-202
Lead indication	AML/MDS
Lead phase	Phase 1
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06325748	Phase 1	Active, not recruiting	Sponsor	Senti Biosciences	—	AML/MDS; CD33 Expressing Hematological Malignancies; FLT3 Expressing Hematological Malignancies	—
NCT06652243	Early Phase 1	Recruiting	Collaborator	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	—	Hepatocellular Carcinoma (HCC)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Senti Biosciences on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

SNTI — Senti Biosciences Holdings Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials